Based on the differential expression of the TGF-β family signaling components in the relapsed AML samples, we went on to compare the mRNA expression levels of TGF-β signaling components between the AML risk groups using the comprehensive data available in the cancer genome atlas (TGCA) database [36]. The gene discussed is TGFB1; the disease is acute myeloid leukemia.